Ethamsylate

Increased risk of thrombosis or hypercoagulability, especially in patients with underlying thrombotic risk factors.

Use with caution. Monitor for signs and symptoms of thrombosis. Consider lower doses of one or both agents if co-administration is necessary.

Theoretical antagonism of anticoagulant effect; may increase thrombosis risk

Monitor coagulation parameters; use with caution

Source: Kimi deep-research + Cla

Potential reduction of thrombolytic efficacy

Avoid concurrent use if possible

Source: Kimi deep-research + Cla

Uncertain, but theoretical possibility of altered bleeding profile. No direct evidence of significant interaction.

Monitor for bleeding or thrombosis. No strong evidence for significant interaction, but caution is prudent.

Uncertain, but theoretical possibility of altered bleeding profile. No direct evidence of significant interaction.

Monitor for bleeding or thrombosis. No strong evidence for significant interaction, but caution is prudent.

May have additive effects on platelet function

Monitor for bleeding or clotting abnormalities

Source: Kimi deep-research + Cla

Both used in obstetric bleeding; no direct interaction

Can be used together in postpartum hemorrhage

Source: Kimi deep-research + Cla

Complementary hemostatic mechanisms; no adverse interaction

Can be combined in severe bleeding protocols

Source: Kimi deep-research + Cla

Uncertain, but theoretical possibility of reduced anticoagulant effect or altered bleeding profile. No direct evidence of significant interaction.

Monitor INR more closely if co-administered, especially at initiation or discontinuation of ethamsylate. No strong evidence for significant interaction, but caution is prudent.